Boston Scientific Corporation
BSX · NYSE
Analyst Consensus
Analyst Ratings Synthesis
Consensus is Buy across 25 analysts, with a stated mean price target of $60. The supplied consensus does not report a low or high target, so target clustering and the width of the distribution cannot be assessed, and the most and least bullish analysts cannot be identified. No named analyst or firm is credited with a rating or price-target revision during the week, so revision direction is unavailable. The substantive investment debate is between Boston Scientific’s quarterly execution, cost-saving program, insider purchase, and future product catalysts, versus management’s reduced full-year outlook and pressure affecting WATCHMAN and electrophysiology. The evidence therefore supports a positive consensus but also a material operating disagreement around the durability of growth.
